Cullinan Therapeutics, Inc.
CGEM
$10.50
$0.302.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.73% | 9.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.65% | 37.82% | |||
| Operating Income | 26.65% | -37.82% | |||
| Income Before Tax | 27.76% | -44.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.76% | -44.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.76% | -44.44% | |||
| EBIT | 26.65% | -37.82% | |||
| EBITDA | 26.68% | -37.88% | |||
| EPS Basic | 27.83% | -44.17% | |||
| Normalized Basic EPS | 27.83% | -44.17% | |||
| EPS Diluted | 27.83% | -44.17% | |||
| Normalized Diluted EPS | 27.83% | -44.17% | |||
| Average Basic Shares Outstanding | 0.10% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||